Wilex AG Closes EUR30 Million Series C Private Equity Round
Privately held Wilex AG of Munich, Germany, announced the closing of its series C private equity round with proceeds of EUR30 million (US$ 39 million). The new capital will allow CEO Prof. Olaf G. Wilhelm and his team at Wilex to further develop its strong clinical pipeline of novel cancer therapies. In particular, the Phase III renal cell carcinoma study of Rencarex, a targeted antibody therapy for the treatment of solid tumors, will be progressed as well as the clinical development of WX-UK1 (the first urokinase inhibitor in the clinic inhibiting metastasis and tumor cell invasion for the treatment of breast cancer and other solid cancers) and of WX-671 (an oral serine protease inhibitor).
BioSpace (http://www.biospace.com/news_story.cfm?StoryID=19999920&full=1)
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May